Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pasithea Therapeutics Corp (NQ: KTTA )

1.170 -0.030 (-2.50%)
Streaming Delayed Price Updated: 12:27 PM EDT, Sep 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54,012
Open 1.150
Bid (Size) 1.160 (971)
Ask (Size) 1.170 (2)
Prev. Close 1.200
Today's Range 1.135 - 1.180
52wk Range 0.8113 - 8.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via Business Wire
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
From Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via Business Wire

Performance

YTD
-34.64%
-34.64%
1 Month
-1.27%
-1.27%
3 Month
+14.72%
+14.72%
6 Month
-16.43%
-16.43%
1 Year
-58.22%
-58.22%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pasithea Therapeutics Awarded A Drug Development Research Grant
Via Benzinga
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC
Via Business Wire
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Via FinancialNewsMedia
Exposures COVID-19
EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox
Via Benzinga
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
Via Benzinga
Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting
From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options
Via Benzinga
Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition
Via Benzinga
This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop?
Via Benzinga
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5
From Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via Business Wire
EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition
Via Benzinga
PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article
Via Investor Brand Network
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Via FinancialNewsMedia
Pasithea Biotech Reports That It's Aiming To Be At The Forefront Of The Mental Health Revolution
Via Benzinga
Virtual Reality Technologies Are Reportedly Unlocking New Possibilities For Mental Healthcare
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Pasithea Reveals Cash Position Of $52.9 Million In Latest Earnings Report, To Expand Pipeline And Fund Operations Well Into 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.